Advances in the therapy of high-grade, glioma at relapse: Pegylated liposomal doxorubicin

Expert Review of Neurotherapeutics

Volumn 2, Issue 5, 2002, Pages 609-615

  Hau, Peter ^a   Dietrich, Joerg ^a   Fabel, Klaus ^a   Bogdahn, Ulrich ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Anthracycline; Caelyx; Doxorubicin; High grade glioma; Pegylated liposomal; Relapse

Indexed keywords

CARBOPLATIN; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ESTRAMUSTINE; ETOPOSIDE; IRINOTECAN; MACROGOL; MARIMASTAT; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; THYMIDINE; TOPOTECAN; TREOSULFAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL MODEL; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG PENETRATION; ENCAPSULATION; GLIOMA; HUMAN; MEDICAL LITERATURE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PROGNOSIS; RECURRENT CANCER; REVIEW; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 0036042708     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.5.609     Document Type: Review

References (52)

1. The WHO classification of tumors of the nervous system
2. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology and End Results (SEER) data, 1973-1991
3. Extent of resection in malignant gliomas: A critical summary
4. Surgery of supratentorial tumors
5. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials
6. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
7. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials
8. The role of chemotherapy in recurrent malignant gliomas: An overview
9. Malignant glioma: Who benefits from adjuvant chemotherapy?
10. Local drug delivery
11. Chemotherapy response criteria in malignant glioma
12. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: A Phase I/II trial
13. A Phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma
14. Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma
15. Phase III data on Caelyx in ovarian cancer
16. A Phase II study of caelyx, liposomal doxorubicin: Lack of activity in patients with advanced gastric cancer
17. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck
18. Randomised Phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
19. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model
20. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
21. Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor bearing animals
22. Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines
23. Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes
24. Tissue distribution and therapeutic effect of iv. free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
25. Phase III study of TLC D-99 (liposome encapsulated doxorubicin versus free doxorubicin in patients with metastatic breast carcinoma
26. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter Phase II trial
27. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy
28. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours
29. Chemosensitivity of glioma cells in vitro: A meta analysis
30. Intratumoral doxorubicin in patients with malignant brain gliomas
31. MDR1 (P-glycoprotein) gene expression-implications for resistance modifier trials
32. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin
33. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model
34. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
35. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A Phase II study of the Italian Sarcoma Group (ISG)
36. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl)
37. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes
38. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
39. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
40. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
41. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
42. A North Central Cancer Treatment Group Phase II trial of topotecan in relapsed gliomas
43. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas
44. Thalidomide as an anti-angiogenic agent in relapsed gliomas
45. A randomized Phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma
46. Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent giioblastoma multiforme
47. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: A Phase II study
48. Treosulfan chemotherapy for recurrent malignant glioma
49. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: A Phase II study
50. Irinotecan treatment for recurrent malignant glioma using an every 3-week regimen
51. A Phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study